Valion Bio, Inc. Common Stock (VBIO) Stock Price

VBIOStock

$1.17

Market Cap$2.28M

P/E—

PEG Ratio—

Div yield—

Beta3.88

VBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-49.52%

VGM Score36.31

Book Value / Share (Quarterly)$2.86

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-14.77%

Cash Flow / Share (Quarterly)$-3.53

Price vs S&P 500 (YTD)-102.61%

Gross Margin (TTM)-58.09%

Net Profit Margin (TTM)-1557.26%

EPS (TTM)$-8.23

10-Day Avg Trading Volume1.55M

EPS Excl Extra (TTM)$-8.23

Revenue Growth (5Y)13.18%

EPS (Annual)$-19.68

ROI (Annual)-223.08%

Gross Margin (Annual)0.26%

Net Profit Margin (5Y Avg)-614.40%

Cash / Share (Quarterly)$0.51

Revenue Growth QoQ (YoY)15.87%

ROA (Last FY)-201.46%

Revenue Growth TTM (YoY)81.20%

EBITD / Share (TTM)$-6.59

ROE (5Y Avg)-194.14%

Operating Margin (TTM)-1495.85%

Cash Flow / Share (Annual)$-3.00

P/B Ratio0.19x

P/B Ratio (Quarterly)0.18x

Net Income / Employee (Annual)$-108,700

Net Interest Coverage (TTM)-5.11x

ROA (TTM)-77.00%

EPS Incl Extra (Annual)$-19.68

Current Ratio (Annual)20.13x

Quick Ratio (Quarterly)0.69x

3-Month Avg Trading Volume1.21M

Revenue / Employee (TTM)$9,300

Tangible BV / Share (Quarterly)$2.32

P/S Ratio (Annual)2.92x

Asset Turnover (Annual)0.28x

52-Week High$32.50

Operating Margin (5Y Avg)-584.97%

EPS Excl Extra (Annual)$-19.68

Quick Ratio (Annual)19.60x

13-Week Price Return-90.73%

Total Debt / Equity (Annual)0.27x

Current Ratio (Quarterly)1.11x

Enterprise Value$7.56M

Revenue / Share Growth (5Y)-10.27%

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$15,000

Inventory Turnover (Annual)1.45x

Pretax Margin (Annual)-725.00%

Cash / Share (Annual)$5.01

3-Month Return Std Dev178.08%

Gross Margin (5Y Avg)2.21%

Net Income / Employee (TTM)$-170,700

ROE (Last FY)-223.08%

Net Interest Coverage (Annual)-17.53x

EPS Basic Excl Extra (Annual)$-19.68

Receivables Turnover (TTM)34.43x

Total Debt / Equity (Quarterly)0.62x

EPS Incl Extra (TTM)$-8.23

Receivables Turnover (Annual)6.42x

ROI (TTM)-82.71%

P/S Ratio (TTM)4.73x

Pretax Margin (5Y Avg)-614.40%

Revenue / Share (Annual)$2.71

Year-to-Date Return-95.37%

5-Day Price Return-30.36%

EPS Normalized (Annual)$-19.68

ROA (5Y Avg)-165.61%

Net Profit Margin (Annual)-725.00%

Month-to-Date Return-58.21%

EBITD / Share (Annual)$-19.69

Operating Margin (Annual)-725.77%

LT Debt / Equity (Annual)0.27x

ROI (5Y Avg)-194.14%

LT Debt / Equity (Quarterly)0.62x

EPS Basic Excl Extra (TTM)$-8.23

P/TBV (Quarterly)0.22x

P/B Ratio (Annual)1.34x

Inventory Turnover (TTM)2.07x

Pretax Margin (TTM)-1504.15%

Book Value / Share (Annual)$26.33

Price vs S&P 500 (13W)-93.41%

Beta3.88x

Revenue / Share (TTM)$0.36

ROE (TTM)-97.34%

52-Week Low$1.11

gGradeB

mGradeF

vgmGradeD

VBIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2023	Nov 14, 2023	-$119.00	-$25.16	+78.86%(+$93.84)
Q2 2023	Aug 14, 2023	-$136.00	-$119.00	+12.50%(+$17.00)
Q1 2023	May 15, 2023	-$187.00	-$187.00	+0.00%(+$0.00)
Q4 2022	Mar 31, 2023	-$527.00	-$391.00	+25.81%(+$136.00)

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VBIOValion Bio, Inc. Common Stock	—	B	F	4.7x	81.2%	-58.1%	—	$1.17
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Valion Bio, Inc. Common Stock

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.